2010 to 2014 | 2015 to 2021 | ||||||
---|---|---|---|---|---|---|---|
Medication (Drug Class): | Drug Indication: | # of ONJ Cases | % of total reported | Medication: | Drug Indication: | # of ONJ Cases | % of total reported |
1. Zoledronic Acid (BP) | Osteoporosis | 1903 | 60.8 | 1. Denosumab (RANKL-i) | Osteoporosis | 3148 | 54.5 |
2. Alendronate (BP) | Osteoporosis | 576 | 18.4 | 2. Zoledronic Acid (BP) | Osteoporosis | 2027 | 35.1 |
3. Denosumab (RANKL-i) | Osteoporosis | 506 | 16.2 | 3. Alendronate (BP) | Osteoporosis | 447 | 7.7 |
4. Pamidronate (BP) | Osteoporosis | 301 | 9.6 | 4. Ibandronate (BP) | Osteoporosis | 200 | 3.5 |
5. Ibandronate (BP) | Osteoporosis | 112 | 3.6 | 5. Lenalidomide (immunomodulator w multiple MOA) | Cancer; immunomodulator with multiple MOA | 150 | 2.6 |
6. Lenalidomide (immunomodulator w multiple MOA) | Cancer; immunomodulator with multiple MOA | 82 | 2.6 | 6. Pamidronate (BP) | Osteoporosis | 115 | 2.0 |
7. Risedronate (BP) | Osteoporosis | 81 | 2.6 | 7. Bevacizumab (anti-VEGF) | Cancer; monoclonal anti-VEGF | 114 | 2.0 |
8. Sunitinib (TKI, antiangiogenic) | Cancer; tyrosine kinase inhibitor | 56 | 1.8 | 8. Prednisolone (CS) | Variety of different indications; many different MOA | 103 | 1.8 |
9. Bevacizumab (anti-VEGF) | Cancer; monoclonal anti-VEGF | 50 | 1.6 | 9. Risedronate (BP) | Osteoporosis | 101 | 1.7 |
10. Prednisolone (CS) | Variety of different indications; many different MOA | 42 | 1.3 | 10. Dexamethasone (CS) | Variety of different indications; many different MOA | 99 | 1.7 |
11. Dexamethasone (CS) | Variety of different indications; many different MOA | 35 | 11.1 | 11. Everolimus (mTOR i) | Cancer; immunomodulator | 90 | 1.6 |
12. Docetaxel (MT depolymerizer) | Cancer; MT depolymerization | 24 | 0.8 | 12. Sunitinib (TKI, antiangiogenesis) | Cancer; tyrosine kinase inhibitor | 78 | 1.4 |
13. Letrozole (aromatase inhibitor) | Cancer; hormonal effects | 15 | 0.5 | 13. Palbociclib (CDK 4/6 inhibitor) | Cancer; hormonal effects | 74 | 1.3 |
14. Methotrexate (antimetabolite) | Cancer; cytotoxic agent | 15 | 0.5 | 14. Docetaxel (MT depolymerizer) | Cancer; MT depolymerization | 54 | 0.9 |
15. Everolimus (mTOR inhibitor) | Cancer; immunomodulator | 12 | 0.4 | 15. Methotrexate (antimetabolite) | Cancer; cytotoxic agent | 51 | 0.9 |
16. Paclitaxel (MT depolymerizer) | Cancer; MT depolymerization | 9 | 0.3 | 16. Prednisone (CS) | Variety of different indications; many different MOA | 47 | 0.8 |
17. Imatinib (TKI) | Cancer; tyrosine kinase inhibitor | 8 | 0.3 | 17. Pomalidomide (unclear; multiple MOA | Cancer; immunomodulator | 29 | 0.5 |
18. Sorafenib (TKI, anti VEGF) | Cancer; immunomodulator | 8 | 0.3 | 18. Radium 223 (emits high energy particles inducing cytotoxic DNA ds breaks in cells) | Cancer; radiotherapy | 25 | 0.4 |
19. Teriparatide (rPTH) | Osteoporosis; hormonal effects | 7 | 0.2 | 19. Nivolumab (PD Rc-1 inhibitor) | Cancer; immunomodulator | 23 | 0.4 |
20. Temsirolimus (mTOR inhibitor) | Cancer; immunomodulator | 6 | 0.2 | 20. Cabozantinib (TKI) | Cancer; tyrosine kinase inhibitor | 22 | 0.4 |